000298355 001__ 298355
000298355 005__ 20251129115931.0
000298355 0247_ $$2doi$$a10.1007/s00062-024-01493-1
000298355 0247_ $$2pmid$$apmid:39880998
000298355 0247_ $$2ISSN$$a1869-1439
000298355 0247_ $$2ISSN$$a0939-7116
000298355 0247_ $$2ISSN$$a1615-6706
000298355 0247_ $$2ISSN$$a1869-1447
000298355 037__ $$aDKFZ-2025-00256
000298355 041__ $$aEnglish
000298355 1001_ $$aMooshage, Christoph M$$b0
000298355 245__ $$aIntradermal Advanced Glycation End-products Relate to Reduced Sciatic Nerve Structural Integrity in Type 2 Diabetes.
000298355 260__ $$aMünchen$$bUrban & Vogel$$c2025
000298355 3367_ $$2DRIVER$$aarticle
000298355 3367_ $$2DataCite$$aOutput Types/Journal article
000298355 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1750251654_2132
000298355 3367_ $$2BibTeX$$aARTICLE
000298355 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298355 3367_ $$00$$2EndNote$$aJournal Article
000298355 500__ $$a2025 Jun;35(2):385-394
000298355 520__ $$aCardiovascular risk management is beneficial, but stringent glycemic control does not prevent the progression of distal sensorimotor polyneuropathy (DSPN). Persistent hyperglycemia-induced alterations and cardiovascular factors may contribute to diabetes-associated nerve damage. This study aimed to evaluate the correlation between skin auto-fluorescence (sAF), an indicator of dermal advanced glycation end-product (AGE) accumulations, cardiovascular risk, and changes in peripheral nerve integrity.Sixty-two individuals with type 2 diabetes (T2D) (20 women and 42 men), including 29 diagnosed with DSPN (7 women and 22 men), and 10 healthy controls (HC) underwent diffusion tensor MR imaging of the sciatic nerve to assess fractional anisotropy (FA), an indicator of nerve structural integrity. sAF measurements were combined with clinical, serological, and electrophysiological evaluations. Arterial stiffness was assessed via pulse wave velocity (PWV).sAF (HC 2.1 ± 0.25 AU, nDSPN 2.3 ± 0.47, DSPN 2.6 ± 0.43; p = 0.005) was higher in individuals with DSPN compared to HC (p = 0.010) and individuals without DSPN (p = 0.035). Within the group of T2D FA correlated negatively with sAF (r = -0.49, p < 0.001), PWV (r = -0.40, p = 0.009) and high-sensitivity troponin T (hsTNT), a marker of microvascular damage (r = -0.39, p < 0.001). In DSPN, sAF correlated positively with hsTNT (r = 0.58, p = 0.005) and with PWV (r = 0.52, p = 0.007), the sciatic nerve's FA correlated negatively with PWV (r = -0.47, p = 0.010).This study is the first to show close correlations between reduced peripheral nerve integrity and both intradermal AGE deposition and arterial stiffness in individuals with T2D. These findings highlight a mechanistic link between glycation-related vascular injury and neuronal damage emphasizing the importance of cardiovascular risk management in preventing DSPN.
000298355 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000298355 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298355 650_7 $$2Other$$aAdvanced glycation end products
000298355 650_7 $$2Other$$aDiabetic neuropathy
000298355 650_7 $$2Other$$aDiffusion tensor imaging
000298355 650_7 $$2Other$$aDistal symmetric polyneuropathy
000298355 650_7 $$2Other$$aMagnetic resonance neurography
000298355 650_7 $$2Other$$aSkin autofluorescence
000298355 7001_ $$aTsilingiris, Dimitrios$$b1
000298355 7001_ $$aSchimpfle, Lukas$$b2
000298355 7001_ $$aFleming, Thomas$$b3
000298355 7001_ $$aHerzig, Stephan$$b4
000298355 7001_ $$aSzendroedi, Julia$$b5
000298355 7001_ $$aHeiland, Sabine$$b6
000298355 7001_ $$aBendszus, Martin$$b7
000298355 7001_ $$aKopf, Stefan$$b8
000298355 7001_ $$0P:(DE-He78)ea7f20e71e3cb1a864c23f2f09f0b0b9$$aKurz, Felix$$b9$$udkfz
000298355 7001_ $$0P:(DE-He78)af2fba3014dac56ccf4188c9879dce19$$aJende, Johann$$b10$$udkfz
000298355 7001_ $$00000-0003-0745-1587$$aKender, Zoltan$$b11
000298355 773__ $$0PERI:(DE-600)2232347-8$$a10.1007/s00062-024-01493-1$$n2$$p385-394$$tClinical neuroradiology$$v35$$x1869-1439$$y2025
000298355 8564_ $$uhttps://inrepo02.dkfz.de/record/298355/files/s00062-024-01493-1.pdf$$yOpenAccess
000298355 8564_ $$uhttps://inrepo02.dkfz.de/record/298355/files/s00062-024-01493-1.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000298355 909CO $$ooai:inrepo02.dkfz.de:298355$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000298355 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea7f20e71e3cb1a864c23f2f09f0b0b9$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000298355 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)af2fba3014dac56ccf4188c9879dce19$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000298355 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000298355 9141_ $$y2025
000298355 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000298355 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000298355 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN NEURORADIOL : 2022$$d2024-12-13
000298355 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000298355 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-13$$wger
000298355 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000298355 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-13
000298355 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000298355 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000298355 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000298355 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000298355 980__ $$ajournal
000298355 980__ $$aVDB
000298355 980__ $$aUNRESTRICTED
000298355 980__ $$aI:(DE-He78)E010-20160331
000298355 9801_ $$aFullTexts